Emerald Foundation Inc C/O Solomon Blum Heymann

40 WALL ST 35TH FLR - NEW YORK - NY 10005, New York

Latest Filing: 2022

Total Assets: $28.51M

Total Giving: $1.43M

Grants: 14

Median Grant: $87,500

EMERALD FOUNDATION INC C/O SOLOMON BLUM HEYMANN is a active grantmaker that only funds pre-selected organizations, distributing $1.4M through 14 grants...

2022 Summary

$28.51M

Total Assets

$1.43M

Funding Awarded

Grants Given

$87,500

Median Grant

$150,000

Largest Grant

$75,000

Smallest Grant

2022 Recipients

Recipient	Award	Location	Purpose
Weill Cornell Medicine	$150,000	New York, NEW YORK	To Identify Regulators Of Lineage Reversion That Impact Resistance To Wnt Targeted Therapies In Colorectal Cancer.
Brigham And Women's Hospital Inc	$150,000	Boston, MASSACHUSETTS	To Uncover And Validate Druggable Targets That Can Be Combined With Mek/Erk Inhibitors To Treat Ras Pathway Driven Malignancies, Especially Melanoma.
Massachusetts Institute Of Technology	$150,000	Cambridge, MASSACHUSETTS	To Investigate The Role Of Diet And Nutrient Availability In Tumor Growth, Progression, And Response To Treatment.
Massachusetts Institute Of Technology	$150,000	Cambridge, MASSACHUSETTS	To Engance Nanoparticle Accumulation In Desired Cell Types To Develop More Effective And Safer Targeted Nanotherapies.
Whitehead Institute For Biomedical Research	$100,000	Cambridge, MASSACHUSETTS	To Investigate The Role Of T Rna Derived Fragments And The Genes They Regulate In Breast Cancer Progression And Metastasis.
Salk Institute For Biological Studies	$100,000	La Jolla, CALIFORNIA	To Investigate The Potential Of Ca19 9 As A Therapeutic Target For Pancreatic Cancer Treatment And To Discover Pharmacological Approaches To Blocking Ca19 9 Production In Malignant Cells.
University Of Guelph	$100,000	New York, NEW YORK	To Identify Combinations Of Commercial Bacterial Isolates That Suppress Klebsiella Pneumoniae In The Colon And The Underlying Cooperative Mechanisms Of This Activity.
Fox Chase Cancer Center	$75,000	Philadelphia, PENNSYLVANIA	To Investigate The Role Of Brg1 Depedent Epigenetic Regulation On Pdac Fibroblast Pro Tumorigenic Functions.
Dana Farber Cancer Institute	$75,000	Boston, MASSACHUSETTS	To Optimize Usp8 Inhibitors And Test Their Activity In Models Of Neurodegenerative Disease, Non Small Cell Lung Cancer, And Other Applicable Systems.
Memorial Sloan Kettering Cancer Center	$75,000	New York, NEW YORK	To Investigate The Molecular Mechanisms Underlying How Endgogenous Dna Modifying Enzymes Lead To Cancer Genome Evolution.
Nyu School Of Medicine	$75,000	New York, NEW YORK	To Investigate How Metabolic Rewiring In Distinct Genetic Subtypes Of Lung Cancer Impacts Immune Cell Infiltration And Leads To Immune Evasion.
University Of California San Francisco	$75,000	San Francisco, CALIFORNIA	To Develop A Small Molecule That Stabilizes Mutant P53 In Cancer And Further Elaborate This Compound With The Ability To Increase Dna Binding Of Bound P53.
Johns Hopkins University	$75,000	Baltimore, MARYLAND	To Investigate How The Colon Microbiota And Host Genetics Intersect To Alter Responsiveness To Immunotherapy In Colorectal Cancer.
Rockefeller Universtity	$75,000	n/a	To Investigate The Role Of T Rna Derived Fragments And The Genes They Regulate In Breast Cancer Progression And Metastasis.

$75,000

$625,000

State

Total

MA

Massachusetts

$625,000
NY

New York

$400,000
CA

California

$175,000
PA

Pennsylvania

$75,000
MD

Maryland

$75,000

Contacts

Name	Phone	Title
ANDREW W HEYMANN	2122677600	PRESIDENT
ANDREW HEYMANN		Signing Officer

Historical Financials

Year	Total Assets	Total Giving	Grants	Median Grant	Max Grant	Min Grant
2022	$28,512,507	$1,425,000	14	$87,500	$150,000	$75,000
2021	$28,954,043	$1,125,000	10	$112,500	$150,000	$75,000
2020	$30,671,225	$1,350,000	11	$150,000	$150,000	$75,000
2019	$32,748,909	$1,350,000	11	$150,000	$150,000	$75,000
2018	$32,711,401	$1,650,000	14	$125,000	$150,000	$75,000